GSK aims to redefine the future of respiratory medicine at the European Respiratory Society ...
GSK to present SWIFT-1 and SWIFT-2 phase III trial data for depemokimab, an ultra-long-acting biologic for severe asthma, at the 2024 ERS International Congress, aiming to achieve long-term clinical remission and advance respiratory medicine with 56 abstracts.
Reference News
GSK aims to redefine the future of respiratory medicine at the European Respiratory Society ...
GSK to present SWIFT-1 and SWIFT-2 phase III trial data for depemokimab, an ultra-long-acting biologic for severe asthma, at the 2024 ERS International Congress, aiming to achieve long-term clinical remission and advance respiratory medicine with 56 abstracts.